myositis: An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
332 |
4. Check minimum number of eventsNone |
332 |
5. Include endpointsNone |
332 |
6. Filter based on genotype QC (FinnGen only) |
299 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Polymyositis
Similar endpoints
↥List of similar endpoints to
Polymyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2237 | 1327 | 876 |
| Only index persons | 1502 | 917 | 585 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 60.94 | 61.53 | 59.95 |
| Only index persons | 57.28 | 57.97 | 56.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 299 | 182 | 117 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.05 |
| Median age at first event (years) | 56.03 | 55.40 | 57.03 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 307
- Matched controls
- 3070
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.2
ICD-10 Finland
Polymyositis
+∞
307.7
270
*
L04AX01
ATC
azathioprine; systemic
49.2
190.8
119
39
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
20.2
161.5
170
178
G72.9
ICD-10 Finland
Myopathy, unspecified
68.2
123.9
69
13
M60.9
ICD-10 Finland
Myositis, unspecified
443.0
98.0
93
*
L04AX03
ATC
methotrexate; systemic
12.2
96.8
123
159
M05BA04
ATC
alendronic acid; oral
10.7
79.7
107
146
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
10.8
73.7
95
122
L04AA06
ATC
mycophenolic acid; systemic
32.2
73.3
49
18
L01BA01
ATC
methotrexate; systemic
16.9
56.6
50
35
H02AB07
ATC
prednisone; oral
6.9
54.6
110
229
P01BA02
ATC
hydroxychloroquine; oral
8.7
54.3
81
122
H02AB06
ATC
prednisolone; systemic
7.8
53.2
249
1094
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.2
52.9
212
812
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
50.4
47
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
90.8
48.7
53
7
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.8
48.3
62
77
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
47.1
44
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
44.9
42
*
M60.8
ICD-10 Finland
Other myositis
494.2
44.4
43
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
40.5
38
*
NXL00
NOMESCO Finland
Biopsy of muscle
222.5
38.8
39
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
63.5
34.1
39
7
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
81.1
32.6
36
5
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.4
31.4
50
79
L88
ICPC
Rheumatoid/seropositive arthritis
8.9
30.1
40
51
M05BA07
ATC
risedronic acid; oral
9.8
29.5
36
41
M35.3
ICD-10 Finland
Polymyalgia rheumatica
12.2
28.9
30
27
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
11.8
27.3
29
27
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.9
25.2
50
98
L04AA01
ATC
[U] ciclosporin
43.9
23.1
28
7
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
23.1
202
1113
L04AD01
ATC
ciclosporin; systemic
21.6
22.7
33
17
7104A
ICD-9 Finland
Diffuse diseases of connective tissue, Polymyositis
+∞
22.1
21
*
71610
ICD-8 Finland
Polymyositis and dermatomyositis, Polymyositis
+∞
22.1
21
*
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
21.1
20
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
9.4
21.0
26
30
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.2
19.7
59
163
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
71.0
17.9
20
*
L28
ICPC
Limited function/disability (L)
3.1
17.4
98
406
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
16.4
120
571
L99
ICPC
Musculoskeletal disease other
12.7
15.9
28
24
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
15.5
65
224
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.6
15.4
59
192
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
30.4
15.4
20
7
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.9
15.3
49
141
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
7.2
15.1
23
34
G72.8
ICD-10 Finland
Other specified myopathies
11.7
14.8
27
25
XG410
NOMESCO Finland
Flow-volume spirometry
5.9
14.6
27
49
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
14.5
120
601
TGC00
NOMESCO Finland
Bronchial lavation
6.1
14.4
26
46
C03CA01
ATC
furosemide; systemic
2.6
14.2
135
722
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
12.9
93
431
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.6
12.9
46
142
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
12.6
12
*
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
12.6
12
*
R06.0
ICD-10 Finland
Dyspnoea
2.5
12.6
117
612
L19
ICPC
Muscle symptom/complaint NOS
9.3
12.3
25
29
Z3226
NOMESCO Finland
Physiotherapist
2.7
12.1
82
367
R13
ICD-10 Finland
Dysphagia
3.6
11.9
42
129
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.3
11.8
32
81
C08CA05
ATC
nifedipine; systemic
3.9
11.7
36
100
R50.9
ICD-10 Finland
Fever, unspecified
2.8
11.7
67
275
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
11.5
11
*
ZX120
NOMESCO Finland
Intravenous
3.3
11.2
47
161
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
5.3
11.2
23
46
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
6.0
11.2
20
35
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.6
11.1
39
119
M79.0
ICD-10 Finland
Rheumatism, unspecified
5.7
11.0
21
39
R4120
NOMESCO Finland
Occupational therapy
3.8
10.9
36
105
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.5
10.8
39
121
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
62.2
10.7
12
*
R4110
NOMESCO Finland
Physiotherapy
2.3
10.7
111
602
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.5
10.5
79
370
G72.4
ICD-10 Finland
Inflammatory myopathy, not elsewhere classified
+∞
10.5
10
*
XX9XE
NOMESCO Finland
Other ultrasound examination
19.6
10.4
15
8
A28
ICPC
Limited function/disability NOS
2.5
10.3
77
360
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.8
10.3
57
229
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.6
10.3
20
38
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.8
10.1
32
91
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.9
9.9
51
196
H26.3
ICD-10 Finland
Drug-induced cataract
20.9
9.9
14
7
318
Kela drug reimbursment
Teriparatide
56.8
9.7
11
*
H05AA02
ATC
teriparatide; parenteral
56.8
9.7
11
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
4.8
9.5
22
49
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.3
9.4
25
62
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
9.4
9
*
A02BC02
ATC
pantoprazole; systemic
2.3
9.3
228
1709
N03AX16
ATC
[U] pregabalin
2.3
9.3
89
462
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
9.3
63
280
M13.9
ICD-10 Finland
Arthritis, unspecified
3.4
9.1
34
108
ZXX01
NOMESCO Finland
Extent of proceudre, 1 unit
24.9
9.0
12
5
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.5
9.0
68
318
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.3
8.9
36
120
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.6
8.9
31
94
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
8.8
76
376
M05BX04
ATC
denosumab; parenteral
3.5
8.8
32
100
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.9
8.8
43
161
EBA10
NOMESCO Finland
Operative extraction of tooth
2.9
8.7
44
167
B07.9
ICD-10 Finland
Verruca simplex
4.8
8.7
20
44
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
4.8
8.7
20
44
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
92.5
8.5
9
*
XPX04
NOMESCO Finland
Angioscopy
92.5
8.5
9
*
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
8.4
8
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
8.4
8
*
M60.0
ICD-10 Finland
Infective myositis
+∞
8.4
8
*
NG4AA
NOMESCO Finland
Lower leg X-ray examination
4.6
8.3
20
46
H02AB09
ATC
hydrocortisone; systemic
7.2
8.2
19
28
N28
ICPC
Limited function/disability (N)
8.5
8.2
17
21
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
22.7
8.1
11
5
R4190
NOMESCO Finland
Nutritional therapy
4.3
7.9
21
52
A41.9
ICD-10 Finland
Sepsis, unspecified
4.5
7.8
19
44
J05AB01
ATC
aciclovir; systemic
2.1
7.7
85
465
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
4.1
7.6
21
54
SPAT1229
SPAT
Assessment of need for aid
3.1
7.5
32
110
XA402
NOMESCO Finland
ENMG
6.3
7.5
19
32
Z50.1
ICD-10 Finland
Other physical therapy
3.2
7.4
30
100
A02BC01
ATC
omeprazole; systemic
2.0
7.4
99
580
XG466
NOMESCO Finland
Sleep oxymetry
4.3
7.4
19
46
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.0
7.4
21
55
N99
ICPC
Neurological disease other
9.7
7.4
14
15
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
7.6
7.3
16
22
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
4.7
7.3
17
38
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.6
7.3
44
184
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
7.2
60
291
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.5
7.1
48
212
R1250
NOMESCO Finland
Evaluation of functional capability
5.7
7.0
19
35
N03AX12
ATC
[U] gabapentin; oral
2.3
7.0
63
315
SAA04
NOMESCO Finland
Special examination of mouth
3.7
7.0
22
62
I50.9
ICD-10 Finland
Heart failure, unspecified
2.3
6.9
61
303
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.4
6.9
25
78
B01AC24
ATC
ticagrelor; oral
4.1
6.8
19
49
G71.08
ICD-10 Finland
Other muscular dystrophy
41.0
6.8
8
*
UJF32
NOMESCO Finland
Coloscopy
2.0
6.7
90
526
JCA55
NOMESCO Finland
Endoscopic dilatation of oesophagus
10.4
6.6
12
12
A07AA02
ATC
nystatin; oral
3.0
6.6
29
102
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
5.9
6.6
17
30
C07AB07
ATC
bisoprolol; oral
1.9
6.5
167
1202
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
6.5
88
514
M79.1
ICD-10 Finland
Myalgia
2.2
6.5
58
289
XW000
NOMESCO Finland
Bone marrow biopsy
3.9
6.5
19
51
JN4BD
NOMESCO Finland
Extensive body CT
2.5
6.5
45
201
H02AB04
ATC
methylprednisolone; systemic
2.3
6.4
55
270
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.7
6.4
36
145
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
6.3
78
441
A01AB10
ATC
natamycin; local oral
5.2
6.3
18
36
N02AX02
ATC
tramadol; systemic, rectal
1.8
6.3
141
971
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
+∞
6.3
6
*
AA1AD
NOMESCO Finland
CT of head and brain
1.9
6.3
104
651
M81.4
ICD-10 Finland
Drug-induced osteoporosis
27.3
6.3
8
*
M05BB03
ATC
alendronic acid and colecalciferol; oral
5.6
6.3
17
32
L29
ICPC
Musculoskeletal sympt/complt other
2.6
6.2
36
147
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.0
6.1
80
461
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
12.9
6.1
10
8
M05BA06
ATC
ibandronic acid; systemic
6.3
6.1
15
25
GD1AD
NOMESCO Finland
Thorax CT examination
2.9
6.0
29
107
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
104
12
130.56
204.26
4.2
1.2
9.72
5.41
u/l
2.12
99
12
114
59
30.14
154.55
1.7
1.2
64.28
—
u/ml
—
12
0
62
14
55.24
106.84
1.3
1.0
—
—
—
0
0
64
25
32.08
94.51
1.3
1.2
133.67
—
u/ml
—
6
0
78
98
10.33
60.89
2.2
1.3
8.72
4.68
iu/ml
0.89
26
22
59
67
10.66
49.21
1.6
1.2
4.96
3.11
u/ml
—
21
8
59
67
10.66
49.21
1.6
1.2
1.75
3.78
u/ml
—
11
5
37
9
46.54
30.71
1.2
1.0
—
—
—
0
0
34
56
6.70
20.30
11.6
8.3
189.43
129.22
iu/ml
—
7
9
237
1503
3.53
20.18
22.9
9.7
4.39
4.10
e9/l
1.14
229
1306
27
11
26.75
19.91
1.1
1.2
—
—
—
0
0
208
1236
3.12
19.54
13.6
6.1
1.21
1.21
mmol/l
1.11
200
1132
221
1372
3.18
18.94
15.7
7.1
1.21
1.21
mmol/l
0.44
203
1187
103
442
3.00
17.16
2.8
1.9
—
—
—
0
0
29
23
13.80
17.03
1.3
1.2
—
—
—
0
0
36
76
5.23
16.59
1.8
1.7
—
—
—
0
0
36
77
5.16
16.34
1.8
1.6
—
—
—
0
0
27
22
13.34
15.69
1.3
1.2
—
—
—
0
0
57
185
3.56
14.93
5.1
3.7
166.12
207.54
ng/l
0.51
51
174
25
20
13.50
14.67
1.3
1.2
—
—
—
0
0
25
20
13.50
14.67
1.3
1.2
—
—
—
0
0
25
21
12.85
14.36
1.3
1.2
—
—
—
0
0
25
21
12.85
14.36
1.3
1.2
—
—
—
0
0
78
317
2.96
14.02
2.7
1.9
—
—
—
0
0
186
1171
2.49
13.48
3.5
2.5
79.58
78.40
nmol/l
0.22
177
1041
151
873
2.44
13.12
5.2
3.2
1271.70
1248.40
ng/l
0.03
139
741
56
198
3.24
12.72
2.3
1.4
—
—
—
0
0
78
335
2.78
12.54
2.7
1.8
—
—
—
0
0
187
1205
2.41
12.51
8.0
4.6
33.79
35.67
g/l
3.65
182
1145
38
106
3.95
12.32
2.8
2.8
—
—
—
0
0
29
66
4.75
12.19
1.3
1.2
—
—
—
0
0
206
1420
2.37
11.32
6.4
3.9
35.21
5.46
estimate
0.39
39
298
28
66
4.57
11.28
1.7
1.5
—
—
—
0
0
22
45
5.19
10.43
1.6
1.4
—
—
—
0
0
202
1411
2.26
10.31
6.4
3.9
0.00
0.00
estimate
-0.00
39
292
21
42
5.29
10.20
1.6
1.4
142.50
167.74
au/ml
—
6
14
22
31
7.56
9.69
2.4
1.8
—
—
—
0
0
202
1434
2.19
9.58
6.5
3.9
0.00
0.01
estimate
0.50
39
276
204
1455
2.20
9.55
10.1
6.8
10.40
11.40
umol/l
1.17
199
1380
20
42
5.02
9.20
1.8
1.6
—
—
—
0
0
24
59
4.33
9.16
1.8
1.5
—
—
—
0
0
67
313
2.46
8.85
18.6
7.6
5.28
5.14
kpa
0.46
62
301
67
313
2.46
8.85
18.6
7.6
10.75
12.24
kpa
1.97
62
303
53
221
2.69
8.84
18.1
7.4
11.50
9.70
mmol/l
0.69
53
212
141
894
2.07
8.77
6.5
3.3
53.41
33.24
u/l
2.05
135
847
43
161
2.94
8.75
2.0
1.7
—
—
—
0
0
255
2031
2.51
8.64
19.9
8.3
70.00
80.31
u/l
5.22
255
1909
22
53
4.39
8.61
1.7
1.8
—
—
—
0
0
126
773
2.07
8.51
4.9
3.2
0.46
0.43
e6/l
0.08
98
547
65
308
2.41
8.29
19.1
7.7
1.92
0.98
mmol/l
0.75
57
257
13
9
15.01
8.27
1.9
2.3
—
—
—
0
0
50
216
2.57
7.73
3.1
2.2
17.25
6.95
ug/l
2.11
44
191
20
50
4.21
7.47
1.4
1.2
215.00
245.85
u/ml
0.16
14
27
45
189
2.62
7.36
2.5
2.5
24.67
18.67
au/ml
—
7
11
93
554
1.97
6.52
6.9
4.1
196.98
239.05
ng/l
0.13
85
452
108
677
1.92
6.52
2.7
2.1
2.73
2.99
mg/l
0.65
96
582
22
66
3.51
6.41
3.4
3.0
0.00
1.97
index
—
9
38
18
47
4.01
6.35
1.3
1.5
—
—
—
0
0
100
617
1.92
6.29
1.3
1.2
0.99
1.50
u/ml
0.42
18
169
83
482
1.99
6.23
4.0
2.9
0.68
1.14
e6/l
1.45
49
252
108
687
1.88
6.17
4.4
2.8
369.80
343.58
umol/l
1.52
102
602
15
25
6.25
6.07
1.1
1.1
—
—
—
0
0
60
312
2.15
6.04
2.7
3.1
7.62
8.53
umol/l
0.20
50
279
16
40
4.16
5.97
1.7
1.6
—
—
—
0
0
19
55
3.62
5.83
1.3
1.5
—
—
—
0
0
36
152
2.55
5.81
4.9
3.6
1.96
1.83
mmol/l
0.08
31
116
126
854
1.81
5.80
3.2
2.6
54.16
66.01
u/l
0.88
120
782
83
500
1.90
5.53
1.5
1.3
58.81
37.99
iu/ml
0.38
29
155
23
79
3.07
5.43
4.4
4.1
1.26
2.25
ratio
0.67
16
41
170
1277
1.74
5.36
18.9
13.1
1.31
1.24
inr
0.81
147
1045
14
26
5.59
5.29
1.1
1.1
—
—
—
0
0
14
27
5.38
5.14
1.9
2.1
—
—
—
0
0
136
968
1.73
5.13
4.3
3.3
2.33
2.36
mmol/l
1.40
130
871
35
156
2.40
5.05
6.8
3.4
24.69
24.29
mmol/l
0.32
35
156
50
261
2.09
4.95
2.4
2.5
471.10
32.49
u/l
0.49
41
214
74
444
1.88
4.94
4.6
3.0
2.68
2.64
e6/l
0.02
42
217
13
25
5.38
4.82
1.8
2.2
—
—
—
0
0
16
47
3.54
4.81
1.5
1.3
—
—
—
0
0
16
47
3.54
4.81
1.5
1.3
—
—
—
0
0
14
30
4.84
4.74
1.4
1.3
—
—
—
0
0
31
135
2.44
4.70
1.5
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
20
70
2.99
4.59
5.2
2.2
0.31
0.35
iu/ml
—
10
35
22
82
2.81
4.52
1.4
1.2
—
—
—
0
0
74
457
1.82
4.47
1.7
1.7
1110.60
1164.45
nmol/l
0.20
60
342
196
1574
1.68
4.47
12.1
4.9
6.62
6.69
mmol/l
0.24
191
1497
22
83
2.78
4.43
1.4
1.2
—
—
—
0
0
93
619
1.72
4.34
2.3
1.7
1.44
1.40
mg/l
0.04
77
500
8
9
9.09
4.30
2.6
3.4
37.94
45.30
g/l
—
8
9
155
1192
1.61
4.05
3.7
2.9
157.57
118.57
ug/l
1.04
149
1109
116
833
1.63
4.00
1.9
1.7
19.79
21.04
nmol/l
0.43
103
691
14
37
3.91
3.95
1.1
1.2
12.00
1.73
u/ml
—
5
11
17
60
2.94
3.86
2.1
1.4
—
—
—
0
0
72
460
1.74
3.84
1.3
1.3
50.20
12.56
u/ml
0.64
19
171
157
1227
1.57
3.73
2.4
2.1
96.47
97.91
pmol/l
0.11
88
617
21
86
2.55
3.63
1.7
1.2
—
—
—
0
0
27
125
2.27
3.60
1.4
1.3
—
—
—
0
0
7
9
7.93
3.57
1.1
1.0
—
—
—
0
0
85
580
1.64
3.53
2.4
2.8
2.46
2.46
mmol/l
0.12
73
523
8
13
6.28
3.52
1.8
1.5
—
—
—
0
0
22
96
2.39
3.35
2.8
1.8
—
—
—
0
0
10
23
4.46
3.34
1.5
1.8
—
—
—
0
0
10
23
4.46
3.34
1.5
1.8
—
—
—
0
0
10
23
4.46
3.34
1.5
1.8
—
—
—
0
0
15
54
2.87
3.30
1.3
1.4
—
—
—
0
0
8
15
5.44
3.21
2.5
3.9
903.87
752.87
u/ml
—
8
15
103
761
1.53
2.99
4.8
3.4
0.74
0.02
estimate
0.47
34
229
5
5
10.13
2.99
1.0
1.2
—
—
—
0
0
5
5
10.13
2.99
2.6
1.6
—
—
—
0
0
8
17
4.80
2.94
1.0
1.0
—
—
—
0
0
17
70
2.51
2.93
1.3
1.7
—
—
—
0
0
19
83
2.37
2.90
1.3
1.4
269.77
265.78
ug/g
0.03
13
46
137
1081
1.48
2.88
6.2
3.8
101.56
31.94
ng/l
2.77
114
783
17
72
2.44
2.78
1.2
1.2
—
—
—
0
0
7
15
4.75
2.61
1.0
1.1
—
—
—
0
0
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
6
11
5.54
2.55
1.8
2.0
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
7
16
4.45
2.49
1.7
1.7
—
—
—
0
0
6
12
5.08
2.41
1.0
1.0
1166.83
1415.25
miu/ml
—
6
12
8
22
3.70
2.38
1.1
1.0
—
—
—
0
0
26
141
1.92
2.36
3.1
3.4
4.26
4.45
pmol/l
0.63
21
123
11
41
2.74
2.23
1.1
1.1
—
—
—
0
0
5
9
5.63
2.22
1.0
1.1
—
—
—
0
0
132
1073
1.40
2.22
6.3
3.8
2.94
0.04
estimate
0.48
34
245
103
804
1.42
2.17
7.4
3.8
0.00
0.00
estimate
-0.00
38
270
9
30
3.06
2.16
1.2
1.2
—
—
—
0
0
7
19
3.74
2.16
1.3
3.7
350.00
1193.21
mg
—
7
19
8
25
3.26
2.11
1.4
1.4
—
—
—
0
0
18
89
2.09
2.10
2.7
1.7
—
—
—
0
0
10
37
2.76
2.09
1.2
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
10
5.06
2.08
1.6
2.1
177.46
127.70
%
—
5
10
14
64
2.24
1.97
1.3
1.3
416.56
10267.57
e6/l
—
9
46
23
128
1.86
1.96
1.1
1.0
—
—
—
0
0
8
27
3.01
1.95
1.9
1.6
—
—
—
0
0
8
27
3.01
1.95
1.9
1.6
—
—
—
0
0
8
27
3.01
1.95
1.9
1.6
—
—
—
0
0
7
22
3.23
1.89
1.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
12
4.22
1.83
1.0
1.3
—
—
—
0
0
268
2507
1.54
1.76
41.1
15.8
21.64
24.51
mg/l
1.01
257
2063
232
2495
0.71
1.71
5.7
5.2
1.37
1.48
mmol/l
4.73
224
2305
80
622
1.39
1.68
7.8
3.9
1.02
1.02
kg/l
0.16
73
413
7
25
2.84
1.66
1.4
1.1
—
—
—
0
0
7
25
2.84
1.66
2.0
1.6
—
—
—
0
0
7
25
2.84
1.66
2.0
1.6
—
—
—
0
0
220
2380
0.73
1.62
5.0
4.5
1.64
1.28
mmol/l
4.05
210
2179
14
70
2.05
1.62
1.6
1.4
—
—
—
0
0
7
26
2.73
1.59
2.0
1.6
—
—
—
0
0
7
26
2.73
1.59
1.0
1.2
—
—
—
0
0
6
21
2.89
1.51
2.7
2.5
—
—
—
0
0
36
246
1.52
1.48
5.8
2.7
4.81
4.37
kpa
0.79
36
239
9
38
2.41
1.47
1.3
1.3
—
—
—
0
0
14
73
1.96
1.46
2.2
1.4
—
—
—
0
0
7
29
2.45
1.40
1.1
1.0
—
—
—
0
0
235
2503
0.74
1.39
5.7
5.4
4.75
4.63
mmol/l
1.02
226
2323
5
17
2.97
1.36
1.6
1.5
—
—
—
0
0
5
18
2.81
1.29
1.6
1.4
—
—
—
0
0
13
70
1.90
1.26
3.2
2.2
114.88
129.91
g/l
—
8
53
5
19
2.66
1.22
4.2
1.8
48.20
80.51
ug/l
—
5
19
5
20
2.52
1.15
1.6
1.5
—
—
—
0
0
12
65
1.88
1.15
11.7
1.9
65.22
57.40
%
0.71
12
65
215
1989
1.27
1.12
5.3
4.4
15.21
14.82
pmol/l
1.48
204
1804
224
2083
1.28
1.12
46.5
20.2
14.51
13.69
%
13.56
224
2060
7
32
2.21
1.08
4.1
3.9
—
—
—
0
0
12
67
1.82
1.06
1.2
1.5
—
—
—
0
0
12
200
0.58
1.02
1.8
1.8
—
—
—
0
0
242
2540
0.78
0.99
6.3
6.2
2.82
2.70
mmol/l
1.53
235
2350
0
29
0.00
0.98
0.0
1.5
—
1.06
—
0
15
0
29
0.00
0.98
0.0
1.5
—
1.23
—
0
15
0
29
0.00
0.98
0.0
1.5
—
0.95
—
0
15
12
69
1.77
0.98
1.1
1.3
—
—
—
0
0
37
280
1.37
0.94
6.6
3.5
—
—
—
0
0
40
309
1.34
0.90
1.4
1.7
1.40
1.51
%
0.65
30
264
13
79
1.67
0.89
1.7
1.6
—
—
—
0
0
6
32
1.89
0.82
1.2
1.2
—
—
—
0
0
105
927
1.20
0.78
4.0
4.0
10.86
8.78
mg/mmol
0.20
65
575
30
227
1.36
0.78
2.4
1.5
—
—
—
0
0
5
26
1.94
0.71
1.6
1.2
67.20
102.77
pmol/l
—
5
26
10
61
1.66
0.69
1.6
1.3
—
—
—
0
0
5
27
1.87
0.68
2.6
2.8
6.54
2.97
nmol/l
—
5
27
135
1233
1.17
0.66
4.0
2.6
—
—
estimate
—
0
0
73
637
1.19
0.62
3.3
2.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
10
65
1.56
0.56
1.6
1.7
—
—
—
0
0
201
2103
0.87
0.51
49.7
20.7
329.02
332.07
g/l
4.72
201
2095
48
414
1.19
0.47
1.5
1.5
—
—
—
0
0
17
217
0.77
0.43
1.5
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
4.0
—
1.00
—
0
18
27
320
0.83
0.37
2.6
4.3
3.23
21.02
ug/l
0.76
22
269
27
227
1.21
0.36
3.0
3.0
77.67
62.32
ml/min/173m2
—
9
92
5
79
0.63
0.36
1.4
1.2
—
—
—
0
0
241
2346
1.13
0.34
6.7
5.5
1.89
1.92
mu/l
0.13
235
2142
7
55
1.28
0.30
7.6
3.1
9.33
9.42
pmol/l
—
7
55
241
2463
0.90
0.29
6.0
5.3
5.82
6.01
mmol/l
1.70
223
2272
11
85
1.31
0.28
1.3
1.2
0.99
0.90
g/l
0.45
11
85
238
2433
0.90
0.28
7.3
6.7
39.96
39.48
mmol/mol
0.45
226
2270
13
159
0.81
0.25
1.8
2.0
3.76
3.50
mmol/l
—
8
126
37
335
1.12
0.22
5.3
4.8
29.36
32.07
%
0.94
28
210
153
1478
1.07
0.21
3.5
2.8
—
—
—
0
0
108
1130
0.93
0.21
2.0
2.0
1.68
1.32
mmol/l
2.34
92
946
10
82
1.23
0.17
1.2
1.1
1.55
1.56
g/l
—
10
82
80
772
1.05
0.11
5.0
5.3
3.95
2.61
ug/l
0.40
72
697
11
97
1.14
0.09
1.3
1.8
—
—
—
0
0
37
389
0.94
0.08
1.9
1.5
—
—
—
0
0
31
294
1.06
0.07
7.5
6.5
—
—
—
0
0
8
78
1.03
0.07
1.1
1.8
—
—
—
0
0
16
151
1.06
0.03
2.7
3.8
54.33
48.84
%
0.38
16
146
48
469
1.03
0.03
3.0
3.2
0.70
0.77
ug/l
0.40
34
304
61
621
0.98
0.03
3.8
4.7
22.21
21.76
%
0.08
29
295
20
194
1.03
0.00
2.4
2.6
11.23
14.35
nmol/l
1.62
20
184
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
1.18
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint M13_POLYMYO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.097 [1.76, 2.5] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.186 |
During the follow-up period (1.1.1998 — 31.12.2019), 247 out of 750 females with M13_POLYMYO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLYMYO | 2.472 [2.02, 3.03] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 217 out of 521 males with M13_POLYMYO died.
Mortality risk
Mortality risk for people of age
years, who have M13_POLYMYO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.119% | 0.47% |
| 5 | 1.131% | 2.714% |
| 10 | 2.947% | 6.901% |
| 15 | 5.887% | 13.095% |
| 20 | 10.067% | 21.454% |
Relationships between endpoints
↥Index endpoint: M13_POLYMYO – Polymyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data